Switching between TNFα antagonists in rheumatoid arthritis: personal experience and review of the literature

  • R. Scrivo | office@pagepress.org
  • F. Conti
  • F.R. Spinelli
  • S. Truglia
  • L. Magrini
  • M. Di Franco
  • F. Ceccarelli
  • G. Valesini

Abstract

The treatment of rheumatoid arthritis (RA) has evolved over the past decade with the introduction of anti-tumor necrosis factor (TNF) α agents, which allowed remarkable advances in controlling signs and symptoms of inflammation and in slowing joint destruction (1-3). However, some patients do not respond or show suboptimal response to the currently available anti- TNFα agents (infliximab, etanercept, and adalimumab) used either as monotherapy or in combination with methotrexate. Furthermore, patients who respond initially may lose efficacy over time (4) or develop adverse events.

Dimensions

Altmetric

PlumX Metrics

Downloads

Download data is not yet available.
Info
Issue
Section
Articles
Statistics
  • Abstract views: 1441

  • PDF: 807
How to Cite
Scrivo, R., Conti, F., Spinelli, F., Truglia, S., Magrini, L., Di Franco, M., Ceccarelli, F., & Valesini, G. (1). Switching between TNFα antagonists in rheumatoid arthritis: personal experience and review of the literature. Reumatismo, 61(2), 107-117. https://doi.org/10.4081/reumatismo.2009.107

Most read articles by the same author(s)

1 2 3 4 > >>